PCI Biotech Holding ASA (STU:4QG) COGS-to-Revenue : 0.00 (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PCI Biotech Holding ASA COGS-to-Revenue?

PCI Biotech Holding ASA's Cost of Goods Sold for the three months ended in Jun. 2023 was €0.00 Mil. Its Revenue for the three months ended in Jun. 2023 was €0.00 Mil.

PCI Biotech Holding ASA's COGS to Revenue for the three months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PCI Biotech Holding ASA's Gross Margin % for the three months ended in Jun. 2023 was N/A%.

PCI Biotech Holding ASA COGS-to-Revenue Historical Data

The historical data trend for PCI Biotech Holding ASA's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA COGS-to-Revenue Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

PCI Biotech Holding ASA Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

PCI Biotech Holding ASA COGS-to-Revenue Calculation

PCI Biotech Holding ASA's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

PCI Biotech Holding ASA's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

PCI Biotech Holding ASA (STU:4QG) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PCI Biotech Holding ASA's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

PCI Biotech Holding ASA COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA (STU:4QG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (STU:4QG) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

PCIB:Norway 4QG:Germany

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (STU:4QG) Headlines

No Headlines